Mapping of Multiple DNA Gains and Losses in Primary Small Cell Lung Carcinomas by Comparative Genomic Hybridization by Ried, Thomas et al.
[CANCER RESEARCH 54. 1801-1806. April I. 1994] 
Mapping of Multiple DNA Gains and Losses in Primary Small Cell Lung 
Carcinomas by Comparative Genomic Hybridization1 
Thomas Ried/ Iver PeterseD, Heidi Holtgreve-Grez, Michael R. Speicher, EveliD Schröck, StaD du MaDoir, aDd 
Thomas Cremer 
Institute o{ Human Genetics, University o{ Heide/berg, INF 328, 69120 Heidelberg [T. R., H. H·G., M. R. S., E. S., T. c.}; Institute o{ Pathology, University o{ Kiel [I. P.I; and 
Angewandte Tumorvirologie, Deutsches Krebs{orschungszentrum, Heidelberg ISo D. M.}, Germany 
ABSTRACf 
Comparative genomic bybridization was applied for a comprebensive 
screening of under- and overrepresentation of genetic material in 13 
autoptic small cell IUDg cancer specimens. The Most abundant genetlc 
cbanges inelude DNA losses of chromosome arms 3p, Sq, lOq, 13q, and 
17p and DNA gains of 3q, Sp, Bq, and 17q. AmpHfication sites in these 
tumors were mapped to 22 chromosome bands. The most frequently 
involved band was 19q13.1 (4 cases). Bands Ip32, 2p23, 7qUol, Bq24, and 
13q33-34 were involved in two cases each. 
INTRODUcnON 
CGH3 is a new method to screen a tumor genome for genetic 
imbalances (I). DNA isolated from the tumor and reference DNA are 
labeled separately with different haptens. Equal amounts of both, 
tumor and reference genomic DNA, are hybridized to normal meta-
phase chromosome preparations together with an excess of unlabeled 
Cotl fraction of human DNA After the detection of the hybridized 
sequences with two fluorochromes, e.g., FITC for the tumor DNA and 
rhodamine for the reference DNA, the differences in f1uorescence 
intensity values of the respective fluorochromes reflect the over- or 
underrepresentation of chromosomal sequences in the tumor genome. 
The technique has been used to detect genetic alterations of entire 
chromosomes or chromosomal subregions, as weil as to map ampli-
fied genes on normal metaphase chromosomes in a variety of solid 
tumors (2-5). Also, formalin-fixed archived tumor material is suitable 
for this molecular cytogenetic technique because it requires solely 
tumor DNA (6). 
Solid tumors account for about 90% of malignancies in man (7). 
Despite this high percentage, relatively few data on specific chromo-
somal aberrations are available as compared to hematological malig-
nancies (8). This discrepancy is mainly due to the difficulties to apply 
cytogenetic banding techniques to solid tumor specimens. Therefore, 
alternative approaches to elucidate genetic changes in solid tumors 
have been introduced. These inelude interphase cytogenetics (9) of 
nuelei in tissue sections or isolated tumor nuelei using whole chro-
mosome paint probes or region-specific probes (10, 11). Also, the 
detection of loss of heterozygosity by means of Southern blot analysis 
or PCR was applied to identify commonly deleted regions in tumor 
genomes (12). However, while these approaches have become very 
useful to evaluate copy number changes of certain chromosomal 
subregions or genes, they are not suitable for the routine assessment 
of genetic changes in entire tumor genomes. 
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Here we report on the identification of DNA alterations in 13 
primary SCLC using CGH. Consensus deletion regions were identi-
fied for chromosomes 3p, 5q, lOq, 13q, and 17p, whereas a consistent 
overrepresentation of chromosomes 3q, 5p, 8q, and 17q was observed. 
The SCLC specimens revealed 22 different amplified regions. The 
chromosomal mapping positions of these amplified sequences were 
determined after CGH on normal metaphase and prometaphase chro-
mosomes. 
MATERIALS AND MEmODS 
Tumor Sampies. Tumor specimens (n = 13) were collected at postmortem 
examination 3-24 h after the patients died. One aliquot of the sampie was 
frozen in liquid nitrogen and kept at -80·C until DNA extraction. Genomic 
DNA was prepared by Proteinase K digestion and phenol-chloroform extrac-
tion (13). A second aliquot was submitted to formalin fixation and paraffin 
embedding. The diagnosis of a SCLC was established in every case according 
to the WHO guidelines on hematoxylin and eosin-stained formalin-fixed tissue 
sections (14). Multiple distant metastases were observed in 12 of 13 cases. One 
patient revealed only locallymph node metastases (case no. 11). 
CGH Analysis. CGH analysis was done according to the protocol by Du 
Manoir et al. (2) with minor modifications. Genomic DNA from a healthy 
male donor was labeled in a standard nick translation reaction substituting 
dTI'P by digoxigenin-11-dUTP (Boehringer Mannheim); tumor DNA was 
labeled accordingly with biotin-16-dUTP (Boehringer Mannheim). The DNase 
I concentration in the labeling reaction was adjusted in order to reveal an 
average fragment size of 500-1 ()()() base pairs. 
For COH, 200 ng of digoxigenin-labeled reference DNA and 200 ng of 
biotin labeled tumor DNA were ethanol precipitated in the presence of 10 ,..,g 
of salmon sperm DNA and 30 p,g of the Cotl fraction of human DNA (BRL). 
This excess of Cotl DNA is required to prevent the ubiquitous hybridization 
of interspersed repetitive sequences contained in the tumor and reference DNA 
probes. The probe mixture was dried and resuspended in 10 ,..,1 hybridization 
solution [50% formamide, 2 X SSC (0.15M NaO, 0.015 M Na-citrate) and 10% 
dextran sulfate). The DNA was denatured at 76·C for 5 min and a1lowed to 
preanneal at 37·C for 60 min. Reference metaphase spreads were prepared 
following standard procedures from peripheral blood lymphocytes of a healthy 
donor (46,XX). The chromosome preparations were denatured separately at 
80·C in 70% deionized formamide and 2 X SSC for 2 min and dehydrated 
through an ethanol series (70, 90, and 100%). The probe mixture was then 
applied to the denatured metaphase chromosomes under a coverslip (18 mm2), 
sealed with rubber cement, and hybridized for 4 days at 37°C. 
Posthybridization steps were performed as described (15). The biotinylated 
sequences were detected with FITC conjugated to avidin (Vector laboratories). 
Probe sequences haptenized with digoxigenin were visualized with anti-
digoxigenin Fab fragments conjugated to rhodamine. Chromosomes were 
counterstained with DAPI and embedded in an antifading agent (DABCO; 
Sigma Chemical Co.) to reduce photobleaching. 
Dlgltallmage Analysis. F1uorescence was detected using a Zeiss Axiophot 
epifluorescence microscope. The f1uorescence banding pattern obtained after 
DAPI staining was used for chromosome identification. FITC and rhodamine 
f1uorescence, specific for the tumor and the reference genome, respectively, 
were quantified as gray level images by a charge-coupled device camera 
(Photometrics, Tucson, AZ). After background f1uorescence measurements, 
f1uorescence ratio images (Fig. 18) were calculated as described (2). Tbe ratio 
profiles of individual reference chromosomes were determined by a program 
that was developed in our laboratory by S. du Manoir (5) and run on a 
Macintosh Quadra 950. Briefly, after the determination of the chromosomal 
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Fig. I. Evaluation of the COH analysis of SCLC case no. 12. A, DAPI-staining of 
normal metaphase chromosomes. The banding paltern was used for chromosome identi-
fication (numbers). B. display of fluorescence ratio image of the same metaphase spread 
as in A after COH with SCLC DNA. A three-color look-up table was chosen for the 
visualization of pixel by pixel F1TC:rhodamine ratios. Blue. balance between the mc 
and rhodamine values. Green, overrepresentation of DNA in the tumor. Red, loss of tumor 
DNA at the corresponding sequences. The chromosomes involved in aberrations in this 
SCLC case are labeled with the respective numbers. Note the consistency of the COH 
results by comparing the values on the homologous chromosomes. 
certain chromosome. Thus, these values are 0.75 and 1.25, respectively. The curve 
shows the ratio profile !hat was cornputated as the mean value of live metaphase 
spreads. The gray boxes in Fig. 2 represent heterochromatic chromosome regions \hat 
cannot be interpreted. In these regions, very 10w ATC and rhodamine tluorescence 
intensities were recorded due to the suppression with Co! 1 DNA AccordingIy, Ouo-
rescence raliai indicating copy number changes oould not be ca1culated. CGH exper-
iments using, as the lest genome, DNA extracted from healthy donors versus the 
reference DNA used in these experiments did not result in values beyond the defined 
thresholds. 
RESULTS 
An example of the experimental data after CGH analysis of SCLC 
case no. 12 is presented in Figs. 1 and 2. The f1uorescence banding 
pattern of a normallymphocyte metaphase spread after DAPI staining 
is shown in Fig. lA. This G-banding pattern was used for chromosome 
identification. Based on the values of the FITC and rhodamine f1uo-
rescence, a ratio image was generated and is displayed using a look-up 
table (Fig. IB). Blue indicates equal copy numbers in the two ge-
nomes. Green represents an overrepresentation in the tumor genome, 
while red is DNA loss. The loss of chromosome 3p is obvious. The 
frequently observed loss of chromosome 5q was accompanied by an 
overrepresentation of 5p. Furthermore, amplification sites could be 
mapped to chromosome bands 3q27-28, 19q13.1, and Xq27. The 
average f1uorescence profile that was calculated for each chromosome 
as the mean value of 5 metaphase spreads is exemplified for this case 
in Fig. 2. Shaded areas represent regions rich in repetitive DNA in 
wh ich the profile could not be interpreted (see "Materials and Meth-
ods"). These average ratio profiles were used for the evaluation of 
chromosomal gains and losses in all cases. 
An overview about all genetic alterations that were detected in 13 
SCLCs is displayed in Fig. 3. Vertical lines on the left side of each 
chromosome idiogram represent loss of genetic material in the tumor, 
whereas those on the right side correspond to again. Changes in 
individual cases can be identified by the case number provided on the 
top of each line. Amplification sites are represented as solid squares 
or bars. 
Chromosome 3 was most frequently affected and showed alter-
ations in all except one case (no. 1). Total or at least partialloss of the 
short arm was a consistent finding. Additionally, the long arm showed 
an overrepresentation in 10 cases. Chromosome 5 revealed genetic 
imbalances in 10 of 13 cases. Again, the loss of genetic material on 
one arm (5q) was often accompanied by a gain on the other chromo-
some arm (5p). This combination occurred in 45% of the cases (6 of 
13). The results of CGH analysis were compared with studies of loss 
of heterozygosity with three markers on chromosome 3p located at 
3p 13-14 (16) and 3p24 (17, 18) and two markers inside the APC gene 
that were assayed by PCR-RFLP (19). In seven cases that were 
informative for these markers, the results were confirmed by CGH-
analysis, e.g., values specific for DNA losses were consistent with 
LOH. In one case, however, LOH on chromosome 3p was not con-
firmed by CGH (see "Discussion"). Chromosome 8 was involved in 7 
of 13 cases (54%). In five of these, an overrepresentation of the long 
arm was observed. The short arm of chromosome 17 was deleted in 8 
axis for each chromosome in every metaphase, individual FITC and rhodamine of 13 cases (61 % ). 
profiles were calculated. These were used for the computation of the ratio Different amplification sites (n = 22) could be mapped to normal 
(F1TC:rhodamine) profiles. Theoretically, a monosomy of certain chromo- chromosomes. For high resolution mapping of the chromosomal 10-
somes in the tumor would result in a ratio value of 0.5 and a trisomy in a value cation of the amplified regions, the CGH analysis was repeated on 
of 1.5. Values above 2 were regarded as amplified regions. The mean of the prometaphase chromosomes. Fig. 4 presents, as an example, a partial 
individual ratio profiles from five metaphase spreads were calculated (Fig. 2). 
The three verticallines on the right side of the chromosome idiogram represent reference prometaphase spread with amplification sites visible at band 
different threshold values between the tumor and the reference DNA. The 8q24.1 harboring the c-myc protooncogene (case no. 3). Most fre-
centralline corresponds to a balanced state, as defined as the most frequently quently, chromosomal band 19q13.1 was involved (4 cases). Se-
observed value. The right and left Iines retlect the threshold values that would quences originating from chromosome bands 1 p32, 2p23, 7q 11.2, 
be present if 50% of the ceD popuJation carries either a monosomy or a trisomy for a 8q24, and 13q33-34 were each amplified in two cases. Amplification 
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Fig. 2. Mean of the ratio profile calculation of five metaphase spreads of case no. 12. The Ihree verlical fines on the righl side of the chromosome idiograms represent different 
values of the fluor.scence intensities between the tumor and the reference DNA. The values are 0.75, I, and 1.25 from left 10 righl. The ratio profile (curve) was calculated as a mean 
value of five metaphase spreads. Gray shaded bous, chromosomal regions rich in heterochromatin that could not be interpreted due to the abundance of highly repetitive DNA. All 
genetic changes that were visible in Fig. 18 were confirmed after mean ratio profile measurements. 
sites that occurred only once were observed at the following locations: 
lq24, lq32, 3q27-28, 5p15, 5p14, 6q21, 6q25, 8q21, 9q22, llql3, 
12p, 14q12-21, 15q24-25, 21q21, 22ql1.2, Xpl1.2, and Xq. 
DISCUSSION 
CGH has recently evolved as a powerful tool for the identification 
of chromosomal gains and losses in genomic DNA from tumor 
sam pIes (1-6). Using CGH, we identified numerous chromosomal 
gains and losses as weIl as DNA amplification sites in 13 cases of 
primary SCLC. 
Lass of genetic material was observed in decreasing frequency on 
chromosomes 3p, 5q, 17p, l3q, IOq, and 4q (Fig. 3). Most consis-
tently, a loss of the short arm of chromosome 3 was observed in 90%. 
This is also the most consistent finding that has been reported previ-
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Fig. 3. Summary oe genetie imbalances detected in 13 primary SCLC. Verticallines on Ibe left side oe eacb ehromosome idiogram represenl 1055 oe genetie malerial in Ibe tumor, 
wbereas lhose on lbe righl side c:orrespond 10 a pin. Cbanges in individual cases can be identified by Ibe case number provided on the lop oe eacb line. Amplificalion sites are 
represenled as solid squares or bars. 
studies involving RFLP markers (25). In one case, the deleted region were reported previously in cytogenetic analysis of SCLC, although 
was restricted to chromosomal bands 3pI2-21.2. However, in the less frequently than in our series of SCLe (27). The fact that, in 
majority of cases the entire short arm was underrepresented. In 10 addition to values reflecting a gain of 3q and 5p, amplification sites 
cases, we observed a simultaneous overrepresentation of the long arm. were mapped to these chromosome arms might favor the hypothesis 
Such a result would be expected in case of an isochromosome 3q that not only the loss of heterozygosity on 3p and 5q but also the low 
formation. Isochromosomes are the cytogenetic correlate of low level level amplification of certain genes on 3q and 5p are important events 
amplification of many genes which might induce a growth advantage in tumor initiation. 
important for tumor initiation (26). Chromosome 5 frequently showed The frequent deletions of chromosomes 3p and 5q in SCLe are 
a similar pattern, i.e., the gain of the short arm was accompanied by indicative for a pivotal mutation in tumor formation. 80th chrome-
the loss of 5q in six cases. This result is suggestive for an isochro- somal arms harbor at least one tumor suppressor gene, i.e., the von 
mosome 5p. 80th an isochromosome 3q and an isochromosome 5p Hippel-Lindau gene on 3p25-26 and the FAP gene on 5q (28-30). 
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Fig. 4. Example of the chromosomal mapping position of an amplification site in 
SCLC cast no. 3. The CGH experiment was performcd on prometaphasc chromosomes. 
Similar 10 Ihe signals after hybridizalion wilb cosmid or Y AC clones, IWO distinguished 
spots were delected, indicating the mapping posiJion of amplified sequences in Ihe lumor 
wilh high resolulion. The signals are observed at chromosome band 8q24.1. 
Tbe contradictory results for loss of 3p material using CGH and 
PCR-RFLP analysis, wh ich we observed in one case (no. 1), can be 
explained by several cytogenetic events: (a) smalI, submicroscopical 
deletions which are beyond the resolution of CGH on metaphase 
chromosomes; (b) mitotic recombination; and (c) chromosome loss 
that was followed by reduplication (31). 80th mitotic recombination 
and reduplication would result in LOH and uniparental disomy that 
would not be accompanied by copy number changes detectable with 
CGH. We observed LOH with primers for chromosomal bands 3p14 
and 3p24. Adeletion of that size would be c1early detectable by CGH. 
Tbus, mitotic recombination or cbromosome reduplication appear to 
be the more Iikely mechanisms that account for the described discrep-
ancy. In all other cases (nos. 3-5, 7-9, and 13) wbere LOH studies 
were informative (19), the results were consistent with the CGH 
analysis. 
Tbe tumor suppressor genes p53 and RB are located on chromo-
somes 17p and 13q, respectively (32). We observed partial and 
complete DNA loss on these chromosomal arms in 8 of 13 (62%) and 
7 of 13 (54%) cases. Tbe chromosome 13 losses were invariably 
accompanied with underrepresentation for 17p. 80th chromosomal 
loci are subject to allelic loss in SCLC as determined by LOH studies 
using RFLPs (33). An additional consensus region involved in losses 
was observed on the chromosomal band IOq24-25 in 5 of 13 cases. 
Tbis region has not been reported previously to be deleted in lung 
cancer but is known to reveal LOH in e.g., gIioblastoma and renal cell 
carcinoma (12). Loss of IIp was not observed in our collective, in 
contrast to previous LOH studies (12). Additional DNA losses were 
found on chromosomes 2p, 4, 8p, 9q, 16, llq, 12q, 18p, 2Op, 21, 
and 22. 
Tbe pattern of chromosomal gains and losses in SCLCs is very 
complex and involves virtually every si te in the genome. Tbis indi-
cates a high genomic instability. Some chromosomes (e.g., 9, 13,21, 
and 22) were involved in both gains and losses of the same subre-
gions. Tbis could possibly be explained as the result of random 
cbromosomal changes which occur early in tumor development. Such 
random changes would be present in the predominant c1one(s) and 
thus could be detected by CGH. However, some chromosomal sites 
were involved with much higher frequencies tban others (see above), 
indicating their specific role in these tumors. It is a striking observa-
tion that chromosome arms 3p, 5q, IOq, and 17p and chromosome 
bands 4q31-35, which were commonly deleted in these tumors, were 
never involved in gains of genetic material. From these data, it 
appears that random gains of these chromosome segments would be 
prohibitive with regard to the formation of SCLCs. An interesting 
observation in this respect was reported by Satoh et al. (34); the 
tumorigenic potential of a lung adenocarcinoma cell line was sup-
pressed after the introduction of chromosomes 3 and 11 by means of 
cell fusion experiments. 
Amplification of protooncogenes are a common feature of solid 
tumors (35, 36). A cytogenetic correlate is provided by double minute 
chromosomes or homogeneously staining regions. In contrast to de-
leted regions, amplifications usually reflect advanced and more ag-
gressive tumor stages. In SCLC, amplification of the myc protoonco-
gene family has been reported (37-39). We mapped the origin of 
amplicons to chromosome bands Ip31-32 (case nos. 3 and 7), 8q24 
(case nos. 3 and 11), and 2p23 (case nos. 6 and 8). Tbese sites harbour 
the L-myc, N-myc, and c-myc protooncogenes, respectively (40). 
Additionally, amplified regions were mapped to chromosomal sites 
containing genes of the ras family, i.e., 12p (v-Ki-ras2). An additional 
site which showed overrepresentation in 4 of 13 cases was identified 
on chromosome 19q13.1. To our knowledge, no protooncogene has 
been mapped so far to this chromosome band. Candidate genes 
include the gene for the transforming growth factor (41) and a zinc 
finger gene (42). Tbe possible involvement of these genes can now be 
tested by means of Southern blot analysis or PCR analysis. 
Recent progress in solid tumor molecular biology, e.g., the identi-
fication of the gene for the familiar tumor syndrome von Hippel-
Lindau (30) and the F AP gene (28, 29), was achieved by positional 
cloning techniques. Tbe identification of the chromosomal mapping 
position of commonly deleted or amplified loci in SCLC, as exem-
plified in this study, will streamline cloning efforts considerably. 
Future work will be focused on the identification of genetic changes 
specific for certain histologically defined lung cancers. Also, CGH of 
a higher case number, including primary tumors and metastatic sites, 
should contribute to identify those genetic aberrations that are respon-
sible for a more aggressive c1inical course, including the potential for 
metastasis. 
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